Welcome to our dedicated page for TRANSLATE BIO news (Ticker: TBIO), a resource for investors and traders seeking the latest updates and insights on TRANSLATE BIO stock.
Telesis Bio Inc. (TBIO) generates news centered on automated DNA and mRNA synthesis technologies, strategic collaborations and corporate developments. The company describes itself as a public company based in San Diego, California, focused on enabling scientists to produce high-fidelity DNA and mRNA directly in their own laboratories using its Gibson SOLA Enzymatic Synthesis platform and BioXp benchtop systems.
News coverage for Telesis Bio often highlights progress and adoption of the Gibson SOLA™ platform, which the company presents as a non-toxic, high-fidelity and scalable enzymatic DNA and mRNA synthesis technology. Announcements have included licensing agreements, such as the deployment of Gibson SOLA at Regeneron Pharmaceuticals’ R&D core facilities, and collaborations that integrate Gibson SOLA with third-party automation platforms to support on-premises biofoundry capabilities.
Investors and researchers following TBIO can expect updates on partnerships and collaborations, including the company’s strategic research collaboration and license agreement with Pfizer related to enzymatic DNA synthesis for potential mRNA-based vaccines and other biopharma products. Additional news may cover agreements with automation and life sciences companies to co-develop and market integrated solutions for high-throughput nucleic acid synthesis.
Corporate and capital markets developments also appear in Telesis Bio’s news flow. Examples include restructuring activities, strategic focus on Gibson SOLA and BioXp mRNA solutions, reverse stock split actions, and the company’s decision to voluntarily delist from The Nasdaq Global Select Market and pursue quotation on over-the-counter markets. For anyone tracking TBIO, the news stream provides context on how the company is positioning its synthesis platforms, managing its cost structure and engaging with partners in synthetic biology and drug discovery workflows.
- Fully-enzymatic, overnight DNA/mRNA synthesis capability
- Reduction in design-to-build timelines from weeks to hours
- High-fidelity and high-purity DNA production
- Compatibility with standard laboratory automation
Telesis Bio has secured up to $21 million in financing through a convertible preferred stock purchase agreement, led by Novalis LifeSciences and Northpond Ventures. The funding includes an initial tranche of approximately $17 million ($8 million cash infusion and $9 million debt conversion) and a potential second tranche of $4 million by March 6, 2026.
The company's newly launched Gibson SOLA™ technology enables overnight DNA and mRNA synthesis using standard automated liquid handling equipment. This platform allows researchers to maintain control of their nucleic acid supply chain, protect IP, and retain valuable data for AI drug discovery models. The technology supports the synthesis of complex constructs necessary for biologics, vaccine, and cell therapy research and development.
The financing provides Telesis Bio with a debt-free balance sheet and sufficient capital to achieve cash-flow breakeven while supporting existing customers and expanding adoption of their next-generation platform.
Telesis Bio and Beckman Coulter Life Sciences have announced a collaboration to revolutionize DNA and mRNA synthesis. The partnership aims to create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach combines Telesis Bio's Gibson SOLA enzymatic reagent platform with Beckman Coulter Life Sciences' automation expertise.
The collaboration integrates Telesis Bio's Gibson SOLA Enzymatic Synthesis technology with the new Biomek Echo One System from Beckman Coulter Life Sciences. This integration ensures rapid, reliable, and highly scalable production of extremely high-fidelity DNA, empowering researchers to achieve greater productivity and innovation in various discovery applications.
The partnership aims to establish local and on-premise DNA foundries that function as digital-to-biologic converters, delivering DNA or mRNA as fast as overnight. This collaboration is expected to set a new standard for on-premises biofoundries and drive forward the next generation of therapeutic and diagnostic advancements.
Telesis Bio Inc. (NASDAQ: TBIO) has announced its decision to voluntarily delist its common stock from the Nasdaq Global Select Market. The company plans to file a Form 25 with the SEC on or about September 20, 2024, with the last trading day expected to be around September 30, 2024. This decision comes after Telesis received notifications from Nasdaq regarding non-compliance with the minimum stockholder's equity requirement and the minimum Market Value of Publicly Held Shares (MVPHS) requirement.
Telesis believes it will be unable to regain compliance with these requirements. Following the delisting, the company's common stock is expected to be quoted on an OTC market, although there is no guarantee of continued trading. Telesis will remain subject to reporting obligations under the Exchange Act.
Telesis Bio Inc. (NASDAQ: TBIO) reported its Q2 and H1 2024 financial results. Key highlights include:
1. Revenue decreased to $1.6 million in Q2 2024 from $7.0 million in Q2 2023.
2. Gross margin dropped to -52% in Q2 2024 from 71% in Q2 2023, primarily due to restructuring charges.
3. Operating expenses improved by 14% to $10.7 million in Q2 2024.
4. Net loss increased to $13.2 million ($7.62 per share) in Q2 2024 from $8.4 million ($5.10 per share) in Q2 2023.
5. The company is advancing its Gibson SOLA reagent platform and continuing its Pfizer collaboration.
6. Telesis Bio divested its Eton subsidiary and underwent restructuring to reduce costs.
7. As of June 30, 2024, the company had $10.3 million in cash and equivalents, with $5.3 million in notes payable.
Telesis Bio Inc. reported their financial results for the first quarter of 2024, highlighting their strategic focus on Gibson SOLA and BioXp mRNA solutions. Revenue decreased compared to the same period last year, with operating expenses reduced by 31%. The company continues to make progress with its collaborations and is optimistic about the future.
Telesis Bio Inc. announced a 1-for-18 reverse stock split to comply with Nasdaq's minimum bid price requirement. The split will consolidate every eighteen shares into one, reducing outstanding shares from 30.1 million to 1.7 million. The reverse stock split will not affect preferred stock but will adjust conversion prices and exercise prices of warrants, options, and equity awards.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of TRANSLATE BIO (TBIO)?
What is the market cap of TRANSLATE BIO (TBIO)?
